- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners
Latest from University of Wisconsin Carbone Cancer Center
ADCs, Triplets, and Transplant Maintain Solid Roles in Multiple Myeloma Therapy
February 24, 2021
Article
Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.
Dr. Schmidt on the Safety and Efficacy of Teclistamab in Multiple Myeloma
February 22, 2021
Video
Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.
Dr. Callander on the Potential Future of Belantamab Mafodotin in Multiple Myeloma
February 19, 2021
Video
Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.
Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma
January 28, 2021
Video
Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.
Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma
January 22, 2021
Video
Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.
Multiple Myeloma: Co-Chaired by Natalie S. Callander, MD and Parameswaran Hari, MD, MRCP
January 13, 2021
Video
Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of multiple myeloma.